Changes in biomarkers with nintedanib plus sildenafil in subjects with IPF by presence of emphysema in the INSTAGE trial

E. White (Ann Arbor, Michigan, United States of America), V. Cottin (Lyon, France), M. Kolb (Hamilton, Ontario, Canada), T. Maher (London, United Kingdom), C. Ittrich (Biberach an der Riss, Germany), C. Diefenbach (Biberach an der Riss, Germany), K. Rohr (Ingelheim am Rhein, Germany), M. Quaresma (Ingelheim am Rhein, Germany), B. Crestani (Paris, France)

Source: Virtual Congress 2020 – Promising biomarkers for idiopathic interstitial pneumonia
Session: Promising biomarkers for idiopathic interstitial pneumonia
Session type: Oral Presentation
Number: 5189
Disease area: Interstitial lung diseases

Congress or journal article abstractWebcastSlide presentationE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
E. White (Ann Arbor, Michigan, United States of America), V. Cottin (Lyon, France), M. Kolb (Hamilton, Ontario, Canada), T. Maher (London, United Kingdom), C. Ittrich (Biberach an der Riss, Germany), C. Diefenbach (Biberach an der Riss, Germany), K. Rohr (Ingelheim am Rhein, Germany), M. Quaresma (Ingelheim am Rhein, Germany), B. Crestani (Paris, France). Changes in biomarkers with nintedanib plus sildenafil in subjects with IPF by presence of emphysema in the INSTAGE trial. 5189

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: